Even with no reduction in BC risk from RRSO, population-based BRCA1/BRCA2 testing was cost-effective, with ICERs of CAD $38 243 (US $27 729.43) per QALY (payer) and CAD $22 686 (US $16 449.28) per QALY (societal). This evidence concerns the gene BRCA1 and breast cancer.